- Fortress Biotech, Inc. (NASDAQ: FBIO) reported a quarterly loss of $0.48 per share, showing improvement from the previous year’s loss of $1.03 per share.
- The company’s revenue exceeded expectations, with $13.14 million reported for the quarter ending March 2025, indicating a positive growth trajectory.
- FBIO announced the commercial launch of Emrosi™ and the FDA’s acceptance of a New Drug Application for CUTX-101, alongside a strategic acquisition of its subsidiary, Checkpoint Therapeutics.
Fortress Biotech, Inc. (NASDAQ: FBIO) is a biopharmaceutical company focused on acquiring, developing, and commercializing innovative pharmaceutical and biotechnology products. The company operates through a network of subsidiaries, each targeting different therapeutic areas. FBIO faces competition from other biotech firms, but it continues to make strides with its diverse product pipeline and strategic partnerships.
FBIO is set to release its quarterly earnings on May 21, 2025, with Wall Street analysts estimating an earnings per share (EPS) of -$0.44. However, the company recently reported a quarterly loss of $0.48 per share, slightly missing the Zacks Consensus Estimate. Despite this, the loss is an improvement from the $1.03 per share loss reported in the same quarter last year.
The company’s revenue is projected to be approximately $11.62 million. However, FBIO delivered a revenue of $13.14 million for the quarter ending March 2025, surpassing the Zacks Consensus Estimate by 27.56%. This revenue figure is a slight increase from the $13.03 million reported in the previous year, showcasing the company’s growth trajectory.
FBIO has initiated the commercial launch of Emrosi™, a treatment for inflammatory lesions of rosacea in adults. Additionally, its subsidiary, Checkpoint Therapeutics, is set to be acquired by Sun Pharma, with a special meeting of Checkpoint stockholders scheduled for May 28, 2025. The FDA has also accepted a New Drug Application for CUTX-101, a treatment for Menkes disease, with a PDUFA goal date set for September 30, 2025.
Despite a negative price-to-earnings (P/E) ratio of -1.08, FBIO’s price-to-sales ratio of 0.90 suggests that its stock is valued at less than its sales revenue. The enterprise value to sales ratio is 0.60, indicating a relatively low valuation compared to its sales. The company’s debt-to-equity ratio of 3.34 highlights a higher level of debt compared to its equity, while a current ratio of 1.72 suggests reasonable liquidity to cover short-term liabilities.
